Cerecor’s $1M Lilly deal put it in the right place at the right time today
Call it collateral — though perhaps temporary — good fortune.
When Alkermes $ALKS whistled up an instant spike for their share price on positive Phase III data for their depression drug ALK-5461, shares of microcap Cerecor $CERC also ignited. The stock had bounced up 56% in premarket trading because it has a mid-stage drug, CERC-501, that has the same mechanism as the Alkermes candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.